{"id":"W4379521655","doi":"10.1136/annrheumdis-2023-eular.1702","title":"POS0668 LOW UVEITIS RATES IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS TREATED WITH BIMEKIZUMAB: POOLED RESULTS FROM PHASE 2B/3 TRIALS","year":2023,"lang":"en","type":"article","venue":"","topic":"Spondyloarthritis Studies and Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Toronto; University Health Network","funders":"UCB Pharma; Incyte; Ipsen; Regeneron Pharmaceuticals; Celgene; Gilead Sciences; Chugai Pharmaceutical; Amgen; Pfizer; Eli Lilly and Company","keywords":"Medicine; Axial spondyloarthritis; Uveitis; Internal medicine; Ankylosing spondylitis; Ophthalmology; Sacroiliitis","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0112052,0.001171691,0.006027157,0.0008144982,0.0003166524,0.002194664,0.0007298951,0.0020529,0.003938442],"category_scores_gemma":[0.009935359,0.0006146758,0.008898489,0.001721446,0.0006744746,0.001197538,0.000676104,0.002254589,0.0006651781],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006438218,"about_ca_system_score_gemma":0.0008348846,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004932447,"about_ca_topic_score_gemma":0.001387591,"domain_scores_codex":[0.9925222,0.004547865,0.001134989,0.0007281841,0.0007589423,0.0003078194],"domain_scores_gemma":[0.9920781,0.003731009,0.002616872,0.0004818589,0.0006039123,0.0004882992],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"meta_analysis","study_design_scores_codex":[0.5983273,0.0009350316,0.04340026,0.03169537,0.1574533,0.0001886019,0.0001658937,0.001928763,0.003278466,0.0004171171,0.01054212,0.1516677],"study_design_scores_gemma":[0.3677312,0.08752529,0.2357652,0.007958547,0.2705262,0.001104975,0.0002798224,0.002142915,0.001710658,0.001592437,0.02339806,0.000264774],"study_design_candidate":"meta_analysis","study_design_consensus":null,"genre_codex":"review","genre_gemma":"empirical","genre_scores_codex":[0.3905192,0.5814967,0.00232007,0.002472025,0.001738565,0.002090584,0.01013786,0.0002177044,0.009007314],"genre_scores_gemma":[0.9079768,0.07533655,0.001631576,0.003328224,0.002329042,0.001752961,0.006490214,0.00008319358,0.001071327],"genre_candidate":"empirical","genre_consensus":null,"teacher_disagreement_score":0.0112052,"threshold_uncertainty_score":0.05925947,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02174529471053193,"score_gpt":0.2907333144511033,"score_spread":0.2689880197405713,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}